This article was originally published in The Gray Sheet
Ann-Marie Lynch, most recently an advisor in the HHS Office of the Assistant Secretary for Planning and Evaluation, will begin Oct. 24 as the trade association's executive VP-Payment & Healthcare Delivery. Priorities will include initiatives in the areas of gainsharing, value-based purchasing and reimbursement rescaling for diagnostics. Lynch has served as staff director for the House Ways & Means Health Subcommittee and as an economist in the Bureau of Policy Development of the Healthcare Financing Administration, the precursor to CMS...
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.